124 related articles for article (PubMed ID: 22969091)
41. P16 reactivation induces anoikis and exhibits antitumour potency by downregulating Akt/survivin signalling in hepatocellular carcinoma cells.
Hu H; Li Z; Chen J; Wang D; Ma J; Wang W; Li J; Wu H; Li L; Wu M; Qian Q; Chen J; Su C
Gut; 2011 May; 60(5):710-21. PubMed ID: 20971978
[TBL] [Abstract][Full Text] [Related]
42. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3091-8. PubMed ID: 12202534
[TBL] [Abstract][Full Text] [Related]
43. shRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosis.
Zhang D; Liu J; Wang Y; Chen J; Chen T
J Cell Biochem; 2011 Nov; 112(11):3140-50. PubMed ID: 21695716
[TBL] [Abstract][Full Text] [Related]
44. Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma.
Liu X; Zhang X; Ji L; Gu J; Zhou M; Chen S
Oncotarget; 2015 Feb; 6(6):4226-38. PubMed ID: 25650661
[TBL] [Abstract][Full Text] [Related]
45. Farnesoid X receptor regulates SULT1E1 expression through inhibition of PGC1α binding to HNF4α.
Wang S; Yuan X; Lu D; Guo L; Wu B
Biochem Pharmacol; 2017 Dec; 145():202-209. PubMed ID: 28912067
[TBL] [Abstract][Full Text] [Related]
46. Regulation of N-Myc downstream regulated gene 2 by bile acids.
Langhi C; Pedraz-Cuesta E; Donate Y; Marrero PF; Haro D; Rodríguez JC
Biochem Biophys Res Commun; 2013 Apr; 434(1):102-9. PubMed ID: 23541942
[TBL] [Abstract][Full Text] [Related]
47. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model.
Deuschle U; Schüler J; Schulz A; Schlüter T; Kinzel O; Abel U; Kremoser C
PLoS One; 2012; 7(10):e43044. PubMed ID: 23056173
[TBL] [Abstract][Full Text] [Related]
48. Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming.
Xie Y; Wang H; Cheng X; Wu Y; Cao L; Wu M; Xie W; Wang G; Hao H
Sci Rep; 2016 Jan; 6():18751. PubMed ID: 26728993
[TBL] [Abstract][Full Text] [Related]
49. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.
Jiang Y; Iakova P; Jin J; Sullivan E; Sharin V; Hong IH; Anakk S; Mayor A; Darlington G; Finegold M; Moore D; Timchenko NA
Hepatology; 2013 Mar; 57(3):1098-106. PubMed ID: 23172628
[TBL] [Abstract][Full Text] [Related]
50. High intensity ERK signal mediates hepatocyte growth factor-induced proliferation inhibition of the human hepatocellular carcinoma cell line HepG2.
Tsukada Y; Miyazawa K; Kitamura N
J Biol Chem; 2001 Nov; 276(44):40968-76. PubMed ID: 11533045
[TBL] [Abstract][Full Text] [Related]
51. Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression.
Liu N; Meng Z; Lou G; Zhou W; Wang X; Zhang Y; Zhang L; Liu X; Yen Y; Lai L; Forman BM; Xu Z; Xu R; Huang W
Mol Endocrinol; 2012 May; 26(5):775-85. PubMed ID: 22474109
[TBL] [Abstract][Full Text] [Related]
52. Down-regulation of CMTM8 induces epithelial-to-mesenchymal transition-like changes via c-MET/extracellular signal-regulated kinase (ERK) signaling.
Zhang W; Mendoza MC; Pei X; Ilter D; Mahoney SJ; Zhang Y; Ma D; Blenis J; Wang Y
J Biol Chem; 2012 Apr; 287(15):11850-8. PubMed ID: 22337876
[TBL] [Abstract][Full Text] [Related]
53. Comparison of liver oncogenic potential among human RAS isoforms.
Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW
Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184
[TBL] [Abstract][Full Text] [Related]
54. Farnesoid X Receptor (FXR) from normal to malignant state.
Koutsounas I; Giaginis C; Theocharis S
Histol Histopathol; 2012 Jul; 27(7):835-53. PubMed ID: 22648540
[TBL] [Abstract][Full Text] [Related]
55. H2 S inhibits apo(a) expression and secretion through PKCα/FXR and Akt/HNF4α pathways in HepG2 cells.
Qu K; Liu YM; He XL; Zhang H; Zhang K; Peng J; Tang YL; Yu XH; Zeng JF; Lei JJ; Wei DH; Wang Z
Cell Biol Int; 2016 Aug; 40(8):906-16. PubMed ID: 27298021
[TBL] [Abstract][Full Text] [Related]
56. δ and γ tocotrienols suppress human hepatocellular carcinoma cell proliferation via regulation of Ras-Raf-MEK-ERK pathway-associated upstream signaling.
Burdeos GC; Ito J; Eitsuka T; Nakagawa K; Kimura F; Miyazawa T
Food Funct; 2016 Oct; 7(10):4170-4174. PubMed ID: 27713963
[TBL] [Abstract][Full Text] [Related]
57. Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma.
Su H; Ma C; Liu J; Li N; Gao M; Huang A; Wang X; Huang W; Huang X
Am J Physiol Gastrointest Liver Physiol; 2012 Dec; 303(11):G1245-53. PubMed ID: 23042943
[TBL] [Abstract][Full Text] [Related]
58. FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway.
Huang X; Zeng Y; Wang X; Ma X; Li Q; Li N; Su H; Huang W
Biochem Biophys Res Commun; 2016 May; 474(2):351-356. PubMed ID: 27109477
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts.
Guan B; Li H; Yang Z; Hoque A; Xu X
Cancer; 2013 Apr; 119(7):1321-9. PubMed ID: 23280144
[TBL] [Abstract][Full Text] [Related]
60. The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines.
Li M; Zhang X; Lu Y; Meng S; Quan H; Hou P; Tong P; Chai D; Gao X; Zheng J; Tong X; Bai J
Cell Death Dis; 2020 Jan; 11(1):31. PubMed ID: 31949131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
